Published in J Natl Cancer Inst on June 15, 2005
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19
The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. Oncogene (2009) 2.14
Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene (2008) 1.82
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Characterization of pulmonary cysts in Birt-Hogg-Dubé syndrome: histopathological and morphometric analysis of 229 pulmonary cysts from 50 unrelated patients. Histopathology (2014) 1.73
Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia. PLoS One (2008) 1.64
Clinical and genetic spectrum of Birt-Hogg-Dube syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature. J Med Genet (2010) 1.61
Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax. J Med Genet (2007) 1.57
Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res (2012) 1.49
Birt-Hogg-Dube syndrome: clinicopathological features of the lung. J Clin Pathol (2012) 1.37
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. Mol Cancer (2010) 1.30
The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dubé gene pathway. Cancer Genet Cytogenet (2008) 1.24
Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription. Oncogene (2011) 1.23
Diagnosis and management of BHD-associated kidney cancer. Fam Cancer (2013) 1.20
The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. Blood (2012) 1.17
Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. J Natl Cancer Inst (2012) 1.16
Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies. Fam Cancer (2013) 1.12
The metabolic basis of kidney cancer. Semin Cancer Biol (2012) 1.09
Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer (2006) 1.08
Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. BMC Med Genomics (2010) 1.06
Molecular genetics and clinical features of Birt-Hogg-Dubé syndrome. Nat Rev Urol (2015) 1.04
Birt-Hogg-Dube syndrome is a novel ciliopathy. Hum Mol Genet (2013) 1.04
The clinical implications of the genetics of renal cell carcinoma. Urol Oncol (2009) 1.03
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
Folliculin regulates ampk-dependent autophagy and metabolic stress survival. PLoS Genet (2014) 1.00
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol (2013) 0.99
Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. Hum Mol Genet (2012) 0.98
Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome. Genes Chromosomes Cancer (2011) 0.94
Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. Cell Rep (2014) 0.94
Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proc Natl Acad Sci U S A (2015) 0.92
Birt-Hogg-Dubé syndrome. Fam Cancer (2013) 0.91
The folliculin mutation database: an online database of mutations associated with Birt-Hogg-Dubé syndrome. Hum Mutat (2009) 0.88
Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep (2011) 0.87
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front Oncol (2014) 0.85
Folliculin mutations are not associated with severe COPD. BMC Med Genet (2008) 0.85
A de novo FLCN mutation in a patient with spontaneous pneumothorax and renal cancer; a clinical and molecular evaluation. Fam Cancer (2013) 0.84
Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol (2009) 0.83
Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. Physiol Rep (2014) 0.82
Repeat partial nephrectomy: surgical, functional and oncological outcomes. Curr Opin Urol (2011) 0.82
The Birt-Hogg-Dubé tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis. Hum Mol Genet (2012) 0.81
Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours. Eur J Hum Genet (2013) 0.81
Precision medicine from the renal cancer genome. Nat Rev Nephrol (2016) 0.80
Pulmonary Neoplasms in Patients with Birt-Hogg-Dubé Syndrome: Histopathological Features and Genetic and Somatic Events. PLoS One (2016) 0.80
Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome. Cancer Sci (2015) 0.79
Birt-Hogg-Dubé syndrome: novel FLCN frameshift deletion in daughter and father with renal cell carcinomas. Fam Cancer (2016) 0.78
Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists. Can Urol Assoc J (2007) 0.78
Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dubé tumors. Mod Pathol (2015) 0.77
Second hits in the FLCN gene in a hereditary renal cancer syndrome in dogs. Mamm Genome (2008) 0.77
Mutation of Fnip1 is associated with B-cell deficiency, cardiomyopathy, and elevated AMPK activity. Proc Natl Acad Sci U S A (2016) 0.77
Case Report: Expanding the tumour spectrum associated with the Birt-Hogg-Dubé cancer susceptibility syndrome. F1000Res (2014) 0.77
Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression. Oncotarget (2015) 0.77
Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome. Expert Opin Orphan Drugs (2014) 0.77
Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol (2011) 0.76
Loss of heterozygosity at the FLCN locus in early renal cystic lesions in dogs with renal cystadenocarcinoma and nodular dermatofibrosis. Mamm Genome (2009) 0.76
Birt-Hogg-Dubé syndrome: a case report and a review of the literature. Eur Clin Respir J (2017) 0.75
Loss of Folliculin Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells (2016) 0.75
Genetic predisposition to kidney cancer. Semin Oncol (2016) 0.75
Familial syndromes coupling with small renal masses. Adv Urol (2008) 0.75
Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression. Oncotarget (2017) 0.75
Sixth BHD Symposium and First International Upstate Kidney Cancer Symposium: latest scientific and clinical discoveries. Oncotarget (2016) 0.75
Haploinsufficiency of the folliculin gene leads to impaired functions of lung fibroblasts in patients with Birt-Hogg-Dubé syndrome. Physiol Rep (2016) 0.75
Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75
Genetic counseling in renal masses. Adv Urol (2008) 0.75
Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families. Fam Cancer (2016) 0.75
The importance of histology and cytogenetics in decision making for renal cell carcinoma. World J Urol (2008) 0.75
FLCN: The causative gene for Birt-Hogg-Dubé syndrome. Gene (2017) 0.75
Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature (2011) 6.57
von Hippel-Lindau disease. Lancet (2003) 6.20
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. N Engl J Med (2015) 5.66
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell (2002) 4.13
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A (2006) 3.51
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol (2008) 3.30
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res (2009) 3.17
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol (2007) 3.07
Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol (2002) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics. Cancer (2012) 2.95
Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet (2003) 2.88
Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol (2013) 2.81
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst (2005) 2.60
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
The amyotrophic lateral sclerosis 8 protein VAPB is cleaved, secreted, and acts as a ligand for Eph receptors. Cell (2008) 2.40
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Nerve-sparing laparoscopic radical prostatectomy: replicating the open surgical technique. Urology (2004) 2.29
The Ter mutation in the dead end gene causes germ cell loss and testicular germ cell tumours. Nature (2005) 2.29
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci U S A (2009) 2.28
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem (2011) 2.24
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst (2008) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med (2007) 2.19